Delcath Systems
Delcath makes the Hepzato Kit, the melphalan percutaneous hepatic perfusion system approved by the FDA in 2023 for uveal melanoma that has spread to the liver, and sells the same device in Europe as Chemosat.
Overview
Delcath Systems, based in New York, developed percutaneous hepatic perfusion, a procedure that isolates the liver's blood supply to deliver high-dose melphalan directly to liver tumours while filtering the drug from blood returning to the body. Its Hepzato Kit was approved by the FDA in August 2023 for adults with uveal melanoma and unresectable liver metastases, the first approved liver-directed therapy for that disease, and the device is marketed in Europe as Chemosat. Company facts are from the official website and FDA approval records.
Scorecard
All companies- approved products +6
- modalities +2
- regions +1